SCHEMBL23701591

SCHEMBL23701591

COC(=O)NC1(c2nnc(-c3ccccc3Nc3ccc(C(F)(F)F)cc3)o2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.46
THRB P10828 1/20 0.39
TP53 P04637 2/20 0.39
GSK3B P49841 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
FAAH O00519 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
FLT1 P17948 1/20 0.36
KDR P35968 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22571342 0.93 ABCG2 (0.42) ABCG2THRBTP53GSK3BRAB9A
SCHEMBL22556385 0.90 ABCG2 (0.43) ABCG2THRBTP53GSK3BRAB9A
SCHEMBL22556438 0.89 ABCG2 (0.41) ABCG2THRBTP53GSK3BRAB9A
SCHEMBL22556440 0.89 ABCG2 (0.41) ABCG2THRBTP53GSK3BKDM4E
SCHEMBL30323517 0.85 GSK3B (0.40) ABCG2TP53GSK3BRAB9ASMN1; SMN2
SCHEMBL22556435 0.85 GSK3B (0.40) ABCG2TP53GSK3BRAB9ASMN1; SMN2
SCHEMBL23701611 0.84 ABCG2 (0.44) ABCG2THRBTP53GSK3BRAB9A
SCHEMBL22571366 0.82 ABCG2 (0.43) ABCG2THRBTP53GSK3BRAB9A
SCHEMBL22556556 0.81 THRB (0.44) ABCG2THRBTP53GSK3BKDM4E
SCHEMBL22556505 0.81 ABCG2 (0.43) ABCG2THRBTP53GSK3BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 ABCG2 2985/4885THRB 1234/4885TP53 4/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 ABCG2 2985/4885THRB 1234/4885TP53 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.